Skip to main content
Top
Published in: Archives of Virology 10/2018

01-10-2018 | Original Article

Overexpression of a virus-like particle influenza vaccine in Eri silkworm pupae, using Autographa californica nuclear polyhedrosis virus and host-range expansion

Authors: Kenichi Maegawa, Toshikatsu Shibata, Ryoji Yamaguchi, Kotomi Hiroike, Uda Zahli Izzati, Kazumichi Kuroda, Shigeo Sugita, Kazunori Kawasaki, Reiko Nerome, Kuniaki Nerome

Published in: Archives of Virology | Issue 10/2018

Login to get access

Abstract

Ecological investigations of silkworms have revealed that Eri silkworms (Samia cynthia ricini) possess useful morphological and ecological characteristics for virus-like particle (VLP) production, namely non-seasonal breeding, longer lengths, and heavier weights than Bombyx mori silkworms. Furthermore, when vector DNA from Bombyx mori nuclear polyhedrosis virus (BmNPV), which is unable to replicate in Sf9 cells from Eri silkworms, was replaced with the Autographa californica nuclear polyhedrosis virus (AcNPV) vector, three improved AcNPV influenza virus recombinants capable of replication in Sf9 cells were obtained. Although VLP antigens produced previously in silkworms were not evaluated individually, the present recombinant Fukushima (FkH5) and Anhui (AnH7) VLP antigens were detected in tissue fluids and fat bodies of Eri silkworms. Here, we aimed to determine the function of the AcNPV vector and P143 gene by expressing recombinants in Sf9 cells and eri silkworm pupae. The FkH5 recombinant produced high yields of haemagglutinin (HA)-positive VLPs, showing a mean HA titre of 1.2 million. Similarly, high production of H7 HA VLPs was observed in the fat bodies of eri silkworm pupae. Antigenic analysis and electron microscopy examination of Eri-silkworm-produced H5 HA VLPs showed characteristic antigenicity and morphology similar to those of the influenza virus. Although FkH5 recombinants possessing the AcNPV vector did not replicate in Bm-N cells, the introduction of the helicase p143 gene from BmNPV resulted in their production in Bm-N and Sf9 cells.
Literature
1.
go back to reference Crosby AW (1976) Flu and the American expeditionary force. Epidemic and peace 1918. Greenwood Press, Westport, CT, pp 145–170 Crosby AW (1976) Flu and the American expeditionary force. Epidemic and peace 1918. Greenwood Press, Westport, CT, pp 145–170
3.
go back to reference Smith W, Andrewes CH, Stuart-Harris CH (1938) The immunization of human volunteers. Spec Rep Ser Med Res Council 228:137–144 Smith W, Andrewes CH, Stuart-Harris CH (1938) The immunization of human volunteers. Spec Rep Ser Med Res Council 228:137–144
5.
go back to reference Stokes J, McGuiness AC, Langner PH, Shaw D (1937) Vaccination against epidemic influenza with active virus of human influenza. Am J Med Sci 194:757–768CrossRef Stokes J, McGuiness AC, Langner PH, Shaw D (1937) Vaccination against epidemic influenza with active virus of human influenza. Am J Med Sci 194:757–768CrossRef
6.
go back to reference Francis T (1953) Vaccination against influenza. Bull WHO 8:725–741PubMed Francis T (1953) Vaccination against influenza. Bull WHO 8:725–741PubMed
7.
go back to reference Francis T, Salk JE, Bruce WM (1946) The protective effect of vaccination against epidemic influenza B. J Am Med Assoc 131:275–278CrossRefPubMed Francis T, Salk JE, Bruce WM (1946) The protective effect of vaccination against epidemic influenza B. J Am Med Assoc 131:275–278CrossRefPubMed
8.
go back to reference Wright PF, Newman G, Kawaoka Y (2013) Orthomyxoviruses. Fields Virol 6:1186–1243 Wright PF, Newman G, Kawaoka Y (2013) Orthomyxoviruses. Fields Virol 6:1186–1243
15.
go back to reference Nerome K, Yoshioka Y, Ishida M et al (1990) Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses. Vaccine 8:503–509CrossRefPubMed Nerome K, Yoshioka Y, Ishida M et al (1990) Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses. Vaccine 8:503–509CrossRefPubMed
16.
go back to reference Iinuma H, Nerome K, Yoshika Y, Okinaga K (1995) Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine. Scand J Immunol 41:1–10CrossRefPubMed Iinuma H, Nerome K, Yoshika Y, Okinaga K (1995) Characteristics of cytotoxic T lymphocytes directed to influenza virus haemagglutinin elicited by immunization with muramyldipeptide-influenza liposome vaccine. Scand J Immunol 41:1–10CrossRefPubMed
17.
go back to reference Nerome K, Kuroda K, Sugita S, Kawasaki K, Iinuma H, Matsuda S, Nerome R (2015) The usefulness of influenza virus-like particle (VLP) vaccine produced in silkworm pupae and virosomes and liposomes prepared by chemical means: from virosome to VLP and the future of vaccines. J Gastrointest Dig Syst 5:1 Nerome K, Kuroda K, Sugita S, Kawasaki K, Iinuma H, Matsuda S, Nerome R (2015) The usefulness of influenza virus-like particle (VLP) vaccine produced in silkworm pupae and virosomes and liposomes prepared by chemical means: from virosome to VLP and the future of vaccines. J Gastrointest Dig Syst 5:1
18.
go back to reference Kojima A, Yasuda A, Asanuma H, Ishikawa T, Takamizawa A, Yasui K, Kurata T (2003) Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus E protein for a second-generation subunit vaccine. J Virol 77:8745–8755CrossRefPubMedPubMedCentral Kojima A, Yasuda A, Asanuma H, Ishikawa T, Takamizawa A, Yasui K, Kurata T (2003) Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus E protein for a second-generation subunit vaccine. J Virol 77:8745–8755CrossRefPubMedPubMedCentral
29.
go back to reference Maeda S, Kamita SG, Kondo A (1993) Host range expansion of Autographa californica nuclear polyhedrosis virus (NPV) following recombination of a 0.6-kilobase-pair DNA fragment originating from Bombyx mori NPV. J Virol 67:6234–6238PubMedPubMedCentral Maeda S, Kamita SG, Kondo A (1993) Host range expansion of Autographa californica nuclear polyhedrosis virus (NPV) following recombination of a 0.6-kilobase-pair DNA fragment originating from Bombyx mori NPV. J Virol 67:6234–6238PubMedPubMedCentral
35.
go back to reference Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, Perdue ML (1999) Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17:2265–2274CrossRefPubMed Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, Perdue ML (1999) Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17:2265–2274CrossRefPubMed
36.
go back to reference Chen YR, Zhong S, Fei Z et al (2013) The transcriptome of the baculovirus Autographa californica multiple nucleopolyhedrovirus in Trichoplusia ni cells. J Virol 87:6391–6405CrossRefPubMedPubMedCentral Chen YR, Zhong S, Fei Z et al (2013) The transcriptome of the baculovirus Autographa californica multiple nucleopolyhedrovirus in Trichoplusia ni cells. J Virol 87:6391–6405CrossRefPubMedPubMedCentral
Metadata
Title
Overexpression of a virus-like particle influenza vaccine in Eri silkworm pupae, using Autographa californica nuclear polyhedrosis virus and host-range expansion
Authors
Kenichi Maegawa
Toshikatsu Shibata
Ryoji Yamaguchi
Kotomi Hiroike
Uda Zahli Izzati
Kazumichi Kuroda
Shigeo Sugita
Kazunori Kawasaki
Reiko Nerome
Kuniaki Nerome
Publication date
01-10-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 10/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-3941-4

Other articles of this Issue 10/2018

Archives of Virology 10/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.